Zongbin Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zongbin Jiang has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Liu Wang
8 shared publications- Ruilin He
Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China
8 shared publications Zhixuan Lan
7 shared publicationsShengrong Xu
Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University
6 shared publicationsRuilin He
5 shared publications- Ruilin He
Department of Pain Management, The Second Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
4 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1833755
Association of platelet-rich plasma combined with dorsal root ganglion-targeted pulsed radiofrequency with outcomes in subacute thoracic herpes zoster neuralgia: a retrospective cohort study
Background: Subacute herpes zoster neuralgia is a clinically important transitional stage before pain becomes fully established as persistent postherpetic neuralgia. Methods: In this single-center retrospective cohort study, patients with subacute thoracic herpes zoster neuralgia treated between January 2024 and December 2025 were identified from routine clinical records. Patients were classified according to the treatment received as PRP + PRF or PRF alone. The primary outcome was the Numerical Rating Scale (NRS) score at 3 months after treatment. Repeated NRS and Pittsburgh Sleep Quality Index (PSQI) measurements were analyzed longitudinally. Secondary outcomes included pregabalin requirement and persistent clinically meaningful zoster-related pain, defined as NRS > 3 at the 3-month post-treatment follow-up. Results: Seventy patients were analyzed, including 36 in the PRP + PRF group and 34 in the PRF group. At 3 months, the observed mean NRS score was lower in the PRP + PRF group than in the PRF group (1.39 ± 1.44 vs. 2.56 ± 1.02). In the prespecified ANCOVA adjusted for baseline NRS, PRP + PRF was associated with a lower 3-month NRS score than PRF alone (adjusted mean difference, −1.13; 95% confidence interval [CI], −1.71 to −0.54; p < 0.001). The association remained directionally consistent in additional multivariable and change-score sensitivity analyses. Significant group-by-time interactions were observed for NRS and PSQI, with lower NRS and PSQI scores in the PRP + PRF group from 1 week through 3 months. Pregabalin requirement at 3 months was lower in the PRP + PRF group ( p = 0.001). Persistent clinically meaningful zoster-related pain at 3 months occurred in 4 of 36 patients (11.1%) in the PRP + PRF group and 7 of 34 patients (20.6%) in the PRF group ( p = 0.336). Conclusion: In this retrospective cohort, PRP combined with DRG-targeted PRF was associated with faster early improvement in pain and sleep and with lower post-treatment pregabalin use than PRF alone. Further prospective studies are needed to confirm these findings and determine whether this approach influences progression to persistent pain and PHN.
- 28 September 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1833755
Open AccessAssociation of platelet-rich plasma combined with dorsal root ganglion-targeted pulsed radiofrequency with outcomes in subacute thoracic herpes zoster neuralgia: a retrospective cohort study
Background: Subacute herpes zoster neuralgia is a clinically important transitional stage before pain becomes fully established as persistent postherpetic neuralgia. Methods: In this single-center retrospective cohort study, patients with subacute thoracic herpes zoster neuralgia treated between January 2024 and December 2025 were identified from routine clinical records. Patients were classified according to the treatment received as PRP + PRF or PRF alone. The primary outcome was the Numerical Rating Scale (NRS) score at 3 months after treatment. Repeated NRS and Pittsburgh Sleep Quality Index (PSQI) measurements were analyzed longitudinally. Secondary outcomes included pregabalin requirement and persistent clinically meaningful zoster-related pain, defined as NRS > 3 at the 3-month post-treatment follow-up. Results: Seventy patients were analyzed, including 36 in the PRP + PRF group and 34 in the PRF group. At 3 months, the observed mean NRS score was lower in the PRP + PRF group than in the PRF group (1.39 ± 1.44 vs. 2.56 ± 1.02). In the prespecified ANCOVA adjusted for baseline NRS, PRP + PRF was associated with a lower 3-month NRS score than PRF alone (adjusted mean difference, −1.13; 95% confidence interval [CI], −1.71 to −0.54; p < 0.001). The association remained directionally consistent in additional multivariable and change-score sensitivity analyses. Significant group-by-time interactions were observed for NRS and PSQI, with lower NRS and PSQI scores in the PRP + PRF group from 1 week through 3 months. Pregabalin requirement at 3 months was lower in the PRP + PRF group ( p = 0.001). Persistent clinically meaningful zoster-related pain at 3 months occurred in 4 of 36 patients (11.1%) in the PRP + PRF group and 7 of 34 patients (20.6%) in the PRF group ( p = 0.336). Conclusion: In this retrospective cohort, PRP combined with DRG-targeted PRF was associated with faster early improvement in pain and sleep and with lower post-treatment pregabalin use than PRF alone. Further prospective studies are needed to confirm these findings and determine whether this approach influences progression to persistent pain and PHN.
- Open Access
- 22 August 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Genetic analyses prioritize a candidate peripheral ferroptosis-related immune–protein network in migraine
Background: Migraine is a disabling neurological disorder with substantial clinical heterogeneity. Ferroptosis-annotated genes encompass functions related to iron and redox homeostasis, lipid peroxidation, and immune regulation, but the genetically supported relationships connecting these processes with peripheral immune-cell phenotypes and circulating proteins have not been systematically examined. Methods: We integrated summary-data-based Mendelian randomization, two-sample Mendelian randomization, colocalization analysis, indirect-effect analysis, PBMC single-cell RNA sequencing, and druggability annotation. Five migraine genome-wide association study datasets were analyzed; GCST90043743 included 166 cases and was treated as a sensitivity dataset. A set of 718 ferroptosis-related genes was evaluated using blood mQTL and eQTL resources and plasma pQTL datasets, while immune-cell MR included 731 immunophenotypes. Evidence was first assessed across molecular data types and migraine outcomes and was then integrated with immune-cell traits, circulating proteins, single-cell expression context, and druggability information. Results: Thirteen genes met the highest cross-omics evidence criteria: ACADSB, ADAMTS13, CDH1, CHMP1A, DPP4, GCH1, GSTM1, ISCU, MAPK9, MAPK14, MUC1, TFRC, and TLR4. A further 25 genes showed recurrent but incomplete cross-omics evidence. Of 2,087 colocalization tests, 313 met the colocalization support criterion, and all 13 highest-evidence genes had at least one result meeting this criterion. Immune-cell MR identified recurrent CD27-related B-cell and CD33-related myeloid traits. Thirty-four matched results from the two indirect-effect analyses were retained; 22 shared CD27-related B-cell traits between GSTM1- or TFRC-related gene-side results and ENPP2-related protein-side results. Additional matched results involved MUC1, myeloid dendritic-cell or naive CD8bright T-cell traits, and HMOX1 or IDO1; ALOX15, CD38-related B-cell or activated Treg traits, and IL1B; and CISD2, a CD27-related B-cell trait, and IFNG. PBMC single-cell RNA sequencing provided peripheral cell-type expression context, and targeted pseudobulk analysis showed increased IFNG expression in CD8+ T cells after Bonferroni correction. Druggability annotation highlighted ENPP2, IDO1, IL1B, and IFNG for translational follow-up. Conclusions: This study prioritizes a candidate peripheral ferroptosis-related immune–protein network associated with migraine susceptibility. The most recurrent relationship involved GSTM1 or TFRC, CD27-related B-cell traits, and ENPP2, with additional myeloid, B-cell/Treg, and inflammatory components. These findings nominate genetically informed candidates for biomarker research, immune-metabolic stratification, and experimental target investigation in migraine.
- 22 August 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Open AccessGenetic analyses prioritize a candidate peripheral ferroptosis-related immune–protein network in migraine
Background: Migraine is a disabling neurological disorder with substantial clinical heterogeneity. Ferroptosis-annotated genes encompass functions related to iron and redox homeostasis, lipid peroxidation, and immune regulation, but the genetically supported relationships connecting these processes with peripheral immune-cell phenotypes and circulating proteins have not been systematically examined. Methods: We integrated summary-data-based Mendelian randomization, two-sample Mendelian randomization, colocalization analysis, indirect-effect analysis, PBMC single-cell RNA sequencing, and druggability annotation. Five migraine genome-wide association study datasets were analyzed; GCST90043743 included 166 cases and was treated as a sensitivity dataset. A set of 718 ferroptosis-related genes was evaluated using blood mQTL and eQTL resources and plasma pQTL datasets, while immune-cell MR included 731 immunophenotypes. Evidence was first assessed across molecular data types and migraine outcomes and was then integrated with immune-cell traits, circulating proteins, single-cell expression context, and druggability information. Results: Thirteen genes met the highest cross-omics evidence criteria: ACADSB, ADAMTS13, CDH1, CHMP1A, DPP4, GCH1, GSTM1, ISCU, MAPK9, MAPK14, MUC1, TFRC, and TLR4. A further 25 genes showed recurrent but incomplete cross-omics evidence. Of 2,087 colocalization tests, 313 met the colocalization support criterion, and all 13 highest-evidence genes had at least one result meeting this criterion. Immune-cell MR identified recurrent CD27-related B-cell and CD33-related myeloid traits. Thirty-four matched results from the two indirect-effect analyses were retained; 22 shared CD27-related B-cell traits between GSTM1- or TFRC-related gene-side results and ENPP2-related protein-side results. Additional matched results involved MUC1, myeloid dendritic-cell or naive CD8bright T-cell traits, and HMOX1 or IDO1; ALOX15, CD38-related B-cell or activated Treg traits, and IL1B; and CISD2, a CD27-related B-cell trait, and IFNG. PBMC single-cell RNA sequencing provided peripheral cell-type expression context, and targeted pseudobulk analysis showed increased IFNG expression in CD8+ T cells after Bonferroni correction. Druggability annotation highlighted ENPP2, IDO1, IL1B, and IFNG for translational follow-up. Conclusions: This study prioritizes a candidate peripheral ferroptosis-related immune–protein network associated with migraine susceptibility. The most recurrent relationship involved GSTM1 or TFRC, CD27-related B-cell traits, and ENPP2, with additional myeloid, B-cell/Treg, and inflammatory components. These findings nominate genetically informed candidates for biomarker research, immune-metabolic stratification, and experimental target investigation in migraine.
- 14 January 2026
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 30 (1) , 21
Peripheral Nerve Stimulation Is Effective in the Management of Trigeminal Pain: A Systematic Review and meta-analysis
Introduction Trigeminal Neuralgia (TN) patients usually experience severe facial pain, leading to a significant reduction in quality of life. Objective To evaluate the effect of peripheral nerve stimulation (PNS) on pain relief in patients with TN. Methods The databases of EMBASE, WEB OF SCIENCE, and PUBMED were searched from inception to 2024 for clinical trials of PNS for TN. The inclusion criteria consisted of any study using PNS to treat TN and reporting outcomes of pain intensity. Risk of bias was assessed using Revised Cochrane Risk of Bias 2.0 and Methodological Index of Non-Randomised Studies (MINORS) tool. Meta-analysis was conducted with RevMan 5.3 and publication bias was evaluated via Egger’s test through STATA17. Results We identified 1,574 citations, and included 9 trials comprising 112 participants. In terms of efficacy, PNS was associated with significant pain relief compared to baseline (MD, −6.23 cm [95% CI, −7.20 to −5.26 cm], P < 0.05, I2 = 89%), with the reduction closely approaching the minimal important difference (MID) threshold of 6.25 cm. Subgroup analysis showed that patients with baseline pain scores ≥ 8 experienced greater pain relief (N = 52, MD, −7.06 cm [95% CI, −8.30 to −5.82 cm], I2 = 87%, p = 0.02) compared to patients with pain scores < 8(N = 60, MD, −4.75 cm [95% CI, −6.22 to −3.28 cm], I2 = 89%) . Conclusions The meta-analysis results showed PNS leads to a statistically and clinically significant improvement in pain. PNS may be a promising approach in the management of TN.
- 14 January 2026
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 30 (1) , 21
Peripheral Nerve Stimulation Is Effective in the Management of Trigeminal Pain: A Systematic Review and meta-analysis
Introduction Trigeminal Neuralgia (TN) patients usually experience severe facial pain, leading to a significant reduction in quality of life. Objective To evaluate the effect of peripheral nerve stimulation (PNS) on pain relief in patients with TN. Methods The databases of EMBASE, WEB OF SCIENCE, and PUBMED were searched from inception to 2024 for clinical trials of PNS for TN. The inclusion criteria consisted of any study using PNS to treat TN and reporting outcomes of pain intensity. Risk of bias was assessed using Revised Cochrane Risk of Bias 2.0 and Methodological Index of Non-Randomised Studies (MINORS) tool. Meta-analysis was conducted with RevMan 5.3 and publication bias was evaluated via Egger’s test through STATA17. Results We identified 1,574 citations, and included 9 trials comprising 112 participants. In terms of efficacy, PNS was associated with significant pain relief compared to baseline (MD, −6.23 cm [95% CI, −7.20 to −5.26 cm], P < 0.05, I2 = 89%), with the reduction closely approaching the minimal important difference (MID) threshold of 6.25 cm. Subgroup analysis showed that patients with baseline pain scores ≥ 8 experienced greater pain relief (N = 52, MD, −7.06 cm [95% CI, −8.30 to −5.82 cm], I2 = 87%, p = 0.02) compared to patients with pain scores < 8(N = 60, MD, −4.75 cm [95% CI, −6.22 to −3.28 cm], I2 = 89%) . Conclusions The meta-analysis results showed PNS leads to a statistically and clinically significant improvement in pain. PNS may be a promising approach in the management of TN.
- Open Access
- 13 January 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1744783
Central effects of short-term spinal cord stimulation in postherpetic neuralgia: a longitudinal fMRI and DTI study
Objective: Postherpetic neuralgia (PHN), a refractory neuropathic pain following herpes zoster reactivation, lacks clear central mechanisms for emerging therapies like short-term spinal cord stimulation (stSCS). This longitudinal study used multimodal neuroimaging to examine the effects of 14-day stSCS on brain function and white matter microstructure in PHN patients, and to identify neural correlates of clinical improvements. Methods: In this longitudinal, single-arm, pre-post study, 17 PHN patients received 14 days of continuous stSCS. Clinical outcomes including pain intensity (Numeric Rating Scale, NRS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS), and sleep quality (Pittsburgh Sleep Quality Index, PSQI), were assessed pre-stSCS and 3 days post-stSCS. Resting-state functional MRI (rs-fMRI) and Diffusion Tensor Imaging (DTI) data were acquired at both time points. Longitudinal changes in amplitude of low-frequency fluctuations (ALFF) and fractional ALFF (fALFF) were analyzed, alongside white matter integrity via TBSS and ROI analysis of key tracts. Results: Post-stSCS, significant improvements occurred in all clinical outcomes (Wilcoxon signed-rank, all p < 0.001). Neuroimaging showed no DTI microstructural changes but significant fALFF increases in regions including the dorsal striatum. Notably, right medial orbitofrontal cortex (mOFC) fALFF increases correlated with NRS reductions (Spearman’s r = 0.71, FDR-corrected p = 0.036). Baseline cingulum integrity (lower FA, higher MD/RD) predicted greater striatal fALFF changes ( r = ±0.75, FDR-corrected p < 0.02). Conclusion: These findings suggest that stSCS’s early clinical benefits in PHN are mediated by rapid functional reorganization rather than immediate microstructural changes. This reorganization appears prominent within fronto-striatal circuits: specifically, mOFC functional changes correlate with analgesia, while baseline cingulum integrity predicts subsequent striatal plasticity. This provides initial mechanistic insights into stSCS and suggest that baseline brain structure could be explored as a potential biomarker for treatment response, warranting validation in larger, controlled cohorts.
- 13 January 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1744783
Open AccessCentral effects of short-term spinal cord stimulation in postherpetic neuralgia: a longitudinal fMRI and DTI study
Objective: Postherpetic neuralgia (PHN), a refractory neuropathic pain following herpes zoster reactivation, lacks clear central mechanisms for emerging therapies like short-term spinal cord stimulation (stSCS). This longitudinal study used multimodal neuroimaging to examine the effects of 14-day stSCS on brain function and white matter microstructure in PHN patients, and to identify neural correlates of clinical improvements. Methods: In this longitudinal, single-arm, pre-post study, 17 PHN patients received 14 days of continuous stSCS. Clinical outcomes including pain intensity (Numeric Rating Scale, NRS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS), and sleep quality (Pittsburgh Sleep Quality Index, PSQI), were assessed pre-stSCS and 3 days post-stSCS. Resting-state functional MRI (rs-fMRI) and Diffusion Tensor Imaging (DTI) data were acquired at both time points. Longitudinal changes in amplitude of low-frequency fluctuations (ALFF) and fractional ALFF (fALFF) were analyzed, alongside white matter integrity via TBSS and ROI analysis of key tracts. Results: Post-stSCS, significant improvements occurred in all clinical outcomes (Wilcoxon signed-rank, all p < 0.001). Neuroimaging showed no DTI microstructural changes but significant fALFF increases in regions including the dorsal striatum. Notably, right medial orbitofrontal cortex (mOFC) fALFF increases correlated with NRS reductions (Spearman’s r = 0.71, FDR-corrected p = 0.036). Baseline cingulum integrity (lower FA, higher MD/RD) predicted greater striatal fALFF changes ( r = ±0.75, FDR-corrected p < 0.02). Conclusion: These findings suggest that stSCS’s early clinical benefits in PHN are mediated by rapid functional reorganization rather than immediate microstructural changes. This reorganization appears prominent within fronto-striatal circuits: specifically, mOFC functional changes correlate with analgesia, while baseline cingulum integrity predicts subsequent striatal plasticity. This provides initial mechanistic insights into stSCS and suggest that baseline brain structure could be explored as a potential biomarker for treatment response, warranting validation in larger, controlled cohorts.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 982
Multi-omics Genetic Prioritization and Cross-species Analysis of Mitochondrial Genes in Trigeminal Neuralgia
To identify mitochondrial genes associated with trigeminal neuralgia (TN) and characterize their expression in patient blood and experimental trigeminal nerve injury. We integrated methylation, expression, and protein quantitative trait loci with FinnGen TN genome-wide association data, focusing on MitoCarta3.0 genes. Summary-data-based Mendelian randomization, heterogeneity testing, colocalization, and tissue-specific analyses prioritized candidates. An exploratory case–control expression analysis measured candidate-gene expression by reverse-transcription quantitative polymerase chain reaction in pretreatment blood from 12 patients with TN and 12 controls; experimental analyses examined blood and selected tissues from six rats with infraorbital nerve chronic constriction injury (ION-CCI) and six sham-operated rats. Longitudinal behavioral testing characterized the injury model. NIT2, HDHD3, and GRHPR overlapped across the three molecular screens. Colocalization supported NIT2 in the anterior cingulate cortex (PP.H4 = 0.949) and GRHPR in tibial nerve (PP.H4 = 0.818). All three genes showed increased expression in patient blood (all false-discovery-rate q < 0.001). HDHD3 and GRHPR also increased in rat blood (both q = 0.0188), and GRHPR increased in the injured infraorbital nerve (q = 0.0076). Genetically predicted higher GRHPR expression was associated with lower TN risk. Human genetics and cross-species expression analyses identify mitochondrial candidates associated with TN and trigeminal nerve injury. The protective genetic direction and injury-associated expression of GRHPR support a hypothesis of compensatory metabolic adaptation in trigeminal pain.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 982
Multi-omics Genetic Prioritization and Cross-species Analysis of Mitochondrial Genes in Trigeminal Neuralgia
To identify mitochondrial genes associated with trigeminal neuralgia (TN) and characterize their expression in patient blood and experimental trigeminal nerve injury. We integrated methylation, expression, and protein quantitative trait loci with FinnGen TN genome-wide association data, focusing on MitoCarta3.0 genes. Summary-data-based Mendelian randomization, heterogeneity testing, colocalization, and tissue-specific analyses prioritized candidates. An exploratory case–control expression analysis measured candidate-gene expression by reverse-transcription quantitative polymerase chain reaction in pretreatment blood from 12 patients with TN and 12 controls; experimental analyses examined blood and selected tissues from six rats with infraorbital nerve chronic constriction injury (ION-CCI) and six sham-operated rats. Longitudinal behavioral testing characterized the injury model. NIT2, HDHD3, and GRHPR overlapped across the three molecular screens. Colocalization supported NIT2 in the anterior cingulate cortex (PP.H4 = 0.949) and GRHPR in tibial nerve (PP.H4 = 0.818). All three genes showed increased expression in patient blood (all false-discovery-rate q < 0.001). HDHD3 and GRHPR also increased in rat blood (both q = 0.0188), and GRHPR increased in the injured infraorbital nerve (q = 0.0076). Genetically predicted higher GRHPR expression was associated with lower TN risk. Human genetics and cross-species expression analyses identify mitochondrial candidates associated with TN and trigeminal nerve injury. The protective genetic direction and injury-associated expression of GRHPR support a hypothesis of compensatory metabolic adaptation in trigeminal pain.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses
Neuropathic pain (NP) is a type of pain resulting from damage or dysfunction of the somatosensory system. Emerging evidence suggests that lipid-lowering drugs may influence the development or progression of NP. This study's objectives are to examine the association between statin use and diabetic peripheral neuropathy (DPN) using NHANES cross-sectional data, and to evaluate whether genetically proxied inhibition of HMGCR, PCSK9, and NPC1L1 is associated with DPN, trigeminal neuralgia (TN), and postherpetic neuralgia (PHN). In the NHANES component, we conducted a cross-sectional analysis of adults with diabetes and dyslipidemia from NHANES 1999-2004 to examine the association between statin use and DPN. In the primary analysis, dyslipidemia was defined using nonfasting/full-sample indicators, and an additional fasting-weight sensitivity analysis was performed using a broader fasting lipid definition. MR analyses were then performed to evaluate the associations of genetically proxied HMGCR, PCSK9, and NPC1L1 inhibition with DPN, TN, and PHN. In NHANES, statin use was not significantly associated with DPN in the primary analysis across progressively adjusted models, and the fasting-weight sensitivity analysis showed directionally similar but still non-significant results. By contrast, MR analyses suggested that genetically proxied HMGCR inhibition was associated with increased odds of DPN (OR = 4.20, 95% CI [2.42, 7.30]) and TN (OR = 1.52, 95% CI [1.14, 2.04]), PCSK9 inhibition with increased odds of DPN (OR = 4.85, 95% CI [2.64, 8.91]), and NPC1L1 inhibition with increased odds of TN (OR = 3.05, 95% CI [1.58, 5.91]). Evidence for PHN was inconsistent across analyses. The NHANES analyses did not identify a statistically significant association between statin use and DPN. By contrast, MR analyses suggested that genetically proxied HMGCR and PCSK9 inhibition may be associated with increased DPN risk, whereas HMGCR and NPC1L1 inhibition may be associated with TN. These associations warrant validation in independent populations and in studies with more precise neuropathic pain phenotyping.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses
Neuropathic pain (NP) is a type of pain resulting from damage or dysfunction of the somatosensory system. Emerging evidence suggests that lipid-lowering drugs may influence the development or progression of NP. This study's objectives are to examine the association between statin use and diabetic peripheral neuropathy (DPN) using NHANES cross-sectional data, and to evaluate whether genetically proxied inhibition of HMGCR, PCSK9, and NPC1L1 is associated with DPN, trigeminal neuralgia (TN), and postherpetic neuralgia (PHN). In the NHANES component, we conducted a cross-sectional analysis of adults with diabetes and dyslipidemia from NHANES 1999-2004 to examine the association between statin use and DPN. In the primary analysis, dyslipidemia was defined using nonfasting/full-sample indicators, and an additional fasting-weight sensitivity analysis was performed using a broader fasting lipid definition. MR analyses were then performed to evaluate the associations of genetically proxied HMGCR, PCSK9, and NPC1L1 inhibition with DPN, TN, and PHN. In NHANES, statin use was not significantly associated with DPN in the primary analysis across progressively adjusted models, and the fasting-weight sensitivity analysis showed directionally similar but still non-significant results. By contrast, MR analyses suggested that genetically proxied HMGCR inhibition was associated with increased odds of DPN (OR = 4.20, 95% CI [2.42, 7.30]) and TN (OR = 1.52, 95% CI [1.14, 2.04]), PCSK9 inhibition with increased odds of DPN (OR = 4.85, 95% CI [2.64, 8.91]), and NPC1L1 inhibition with increased odds of TN (OR = 3.05, 95% CI [1.58, 5.91]). Evidence for PHN was inconsistent across analyses. The NHANES analyses did not identify a statistically significant association between statin use and DPN. By contrast, MR analyses suggested that genetically proxied HMGCR and PCSK9 inhibition may be associated with increased DPN risk, whereas HMGCR and NPC1L1 inhibition may be associated with TN. These associations warrant validation in independent populations and in studies with more precise neuropathic pain phenotyping.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 7053-7063
Digital Cognitive Behavioral Therapy for Insomnia in Cancer Pain Patients: Protocol for a Prospective, Randomized Controlled Trial
Introduction: Insomnia is one of the most common complications in cancer patients, and Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for insomnia in the general population and patients with a cancer diagnosis. Traditional CBT-I is susceptible to limitations such as geography, physical condition, and cost of access to healthcare, hindering its widespread adoption. With the application and development of digitalization and artificial intelligence providing opportunities for the administration and promotion of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) to provide a better sleep treatment option for cancer pain patients, this study aims to evaluate its efficacy. Methods: This single-center trial will randomize 158 cancer pain patients with insomnia to DCBT-I or sleep hygiene education (1:1) to test if DCBT-I is superior for improving sleep quality. Assessments will also cover pain intensity, mental health, and quality of life. Discussion: This study will provide valuable clinical evidence that DCBT-I helps to improve sleep quality, pain intensity, mental health, and quality of life in cancer pain patients suffering from insomnia and contributes to the dissemination of this non-pharmacological alternative treatment option. Conclusion: This study protocol outlines a rigorous randomized controlled trial to evaluate the efficacy of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) compared to Sleep Hygiene Education (SHE) in cancer pain patients with comorbid insomnia. The Resleep smartphone-based intervention integrates evidence-based CBT-I components (sleep restriction, stimulus control, cognitive restructuring, and relaxation training) to address the limitations of traditional therapy, such as accessibility and cost. Clinical Trial Registration: This study is a registered clinical trial. Registry: Chinese Clinical Trial Registry (ChiCTR), listed in the WHO International Clinical Trials Registry Platform (WHO ICTRP). Trial Registration Number: ChiCTR2500096855. Date of Registration: 07 February 2025. Registration Url: https://www.chictr.org.cn/index.html.
- 1 December 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 7053-7063
Open AccessDigital Cognitive Behavioral Therapy for Insomnia in Cancer Pain Patients: Protocol for a Prospective, Randomized Controlled Trial
Introduction: Insomnia is one of the most common complications in cancer patients, and Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for insomnia in the general population and patients with a cancer diagnosis. Traditional CBT-I is susceptible to limitations such as geography, physical condition, and cost of access to healthcare, hindering its widespread adoption. With the application and development of digitalization and artificial intelligence providing opportunities for the administration and promotion of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) to provide a better sleep treatment option for cancer pain patients, this study aims to evaluate its efficacy. Methods: This single-center trial will randomize 158 cancer pain patients with insomnia to DCBT-I or sleep hygiene education (1:1) to test if DCBT-I is superior for improving sleep quality. Assessments will also cover pain intensity, mental health, and quality of life. Discussion: This study will provide valuable clinical evidence that DCBT-I helps to improve sleep quality, pain intensity, mental health, and quality of life in cancer pain patients suffering from insomnia and contributes to the dissemination of this non-pharmacological alternative treatment option. Conclusion: This study protocol outlines a rigorous randomized controlled trial to evaluate the efficacy of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) compared to Sleep Hygiene Education (SHE) in cancer pain patients with comorbid insomnia. The Resleep smartphone-based intervention integrates evidence-based CBT-I components (sleep restriction, stimulus control, cognitive restructuring, and relaxation training) to address the limitations of traditional therapy, such as accessibility and cost. Clinical Trial Registration: This study is a registered clinical trial. Registry: Chinese Clinical Trial Registry (ChiCTR), listed in the WHO International Clinical Trials Registry Platform (WHO ICTRP). Trial Registration Number: ChiCTR2500096855. Date of Registration: 07 February 2025. Registration Url: https://www.chictr.org.cn/index.html.
- Open Access
- 9 October 2025
- Published by Science Publishing Group in International Journal of Pain Research
- Vol. 1 (4) , 172-187
Consensus of Chinese Painologist Experts on Diagnosis and Treatment of Phantom Limb Pain
Phantom limb pain (PLP), defined as neuropathic pain perceived in the missing portion of an amputated limb, represents a common and refractory condition significantly impairing patient rehabilitation and quality of life. Its pathogenesis is multifactorial, involving complex interactions between peripheral mechanisms (e.g., neuroma formation, ectopic discharges), central nervous system reorganization (including cortical remapping and spinal cord sensitization), and psychological components. Patients frequently present with heterogeneous pain descriptors, such as burning, shooting, or cramping sensations, which often coexist with residual limb pain, complicating clinical assessment. Despite the availability of diverse therapeutic interventions-ranging from pharmacotherapy (e.g., gabapentinoids, antidepressants, NMDA receptor antagonists) and physical modalities (e.g., transcranial magnetic stimulation, mirror therapy) to interventional procedures (e.g., nerve blocks, neuromodulation) and psychological approaches-treatment outcomes remain variable, and standardized clinical guidelines are lacking. This consensus, formulated by a panel of Chinese pain specialists, systematically reviews contemporary evidence on the epidemiology, pathophysiology, diagnosis, and management of PLP. It aims to establish practical, evidence-based recommendations to guide the standardized diagnosis and stratified treatment of PLP, thereby optimizing therapeutic efficacy and improving functional outcomes for affected individuals.
- 9 October 2025
- Published by Science Publishing Group in International Journal of Pain Research
- Vol. 1 (4) , 172-187
Open AccessConsensus of Chinese Painologist Experts on Diagnosis and Treatment of Phantom Limb Pain
Phantom limb pain (PLP), defined as neuropathic pain perceived in the missing portion of an amputated limb, represents a common and refractory condition significantly impairing patient rehabilitation and quality of life. Its pathogenesis is multifactorial, involving complex interactions between peripheral mechanisms (e.g., neuroma formation, ectopic discharges), central nervous system reorganization (including cortical remapping and spinal cord sensitization), and psychological components. Patients frequently present with heterogeneous pain descriptors, such as burning, shooting, or cramping sensations, which often coexist with residual limb pain, complicating clinical assessment. Despite the availability of diverse therapeutic interventions-ranging from pharmacotherapy (e.g., gabapentinoids, antidepressants, NMDA receptor antagonists) and physical modalities (e.g., transcranial magnetic stimulation, mirror therapy) to interventional procedures (e.g., nerve blocks, neuromodulation) and psychological approaches-treatment outcomes remain variable, and standardized clinical guidelines are lacking. This consensus, formulated by a panel of Chinese pain specialists, systematically reviews contemporary evidence on the epidemiology, pathophysiology, diagnosis, and management of PLP. It aims to establish practical, evidence-based recommendations to guide the standardized diagnosis and stratified treatment of PLP, thereby optimizing therapeutic efficacy and improving functional outcomes for affected individuals.
- Open Access
- 9 October 2025
- Published by Science Publishing Group in International Journal of Pain Research
- Vol. 1 (4) , 157-171
Chinese Expert Consensus on Percutaneous Balloon Compression for Trigeminal Neuralgia (2022)
Percutaneous balloon compression (PBC) is recognized as a simple, safe, and effective intervention for trigeminal neuralgia (TN) and has been widely adopted in clinical practice across China. However, variations in its application exist among different regions. To standardize procedural protocols and enhance clinical outcomes, a multidisciplinary panel of Chinese experts from pain medicine and neurosurgery collaboratively developed this clinical expert consensus. The consensus formulation involved a systematic literature review of major databases, including Wanfang and PubMed, among others, and focusing on high-quality evidence such as systematic reviews, meta-analyses, randomized controlled trials, expert consensus statements, and clinical guidelines. Using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and structured consensus conference methods, the panel held iterative discussions and conducted voting sessions to finalize the recommendations. This document summarizes key aspects of PBC, including relevant anatomy, mechanisms of action, indications, contraindications, detailed operative techniques, and efficacy evaluation. It aims to serve as a practical reference for clinicians to standardize and optimize the use of PBC in the treatment of trigeminal neuralgia.
- 9 October 2025
- Published by Science Publishing Group in International Journal of Pain Research
- Vol. 1 (4) , 157-171
Open AccessChinese Expert Consensus on Percutaneous Balloon Compression for Trigeminal Neuralgia (2022)
Percutaneous balloon compression (PBC) is recognized as a simple, safe, and effective intervention for trigeminal neuralgia (TN) and has been widely adopted in clinical practice across China. However, variations in its application exist among different regions. To standardize procedural protocols and enhance clinical outcomes, a multidisciplinary panel of Chinese experts from pain medicine and neurosurgery collaboratively developed this clinical expert consensus. The consensus formulation involved a systematic literature review of major databases, including Wanfang and PubMed, among others, and focusing on high-quality evidence such as systematic reviews, meta-analyses, randomized controlled trials, expert consensus statements, and clinical guidelines. Using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and structured consensus conference methods, the panel held iterative discussions and conducted voting sessions to finalize the recommendations. This document summarizes key aspects of PBC, including relevant anatomy, mechanisms of action, indications, contraindications, detailed operative techniques, and efficacy evaluation. It aims to serve as a practical reference for clinicians to standardize and optimize the use of PBC in the treatment of trigeminal neuralgia.
- Open Access
- 5 August 2025
- Published by Elsevier in Obesity Research & Clinical Practice
- Vol. 19 (4) , 303-309
Association between waist-to-height ratio and headache symptoms in U.S. youth: A nationwide cross-sectional study
- 5 August 2025
- Published by Elsevier in Obesity Research & Clinical Practice
- Vol. 19 (4) , 303-309
Open AccessAssociation between waist-to-height ratio and headache symptoms in U.S. youth: A nationwide cross-sectional study